Who is sponsoring NCT06682728?

NCT06682728 is sponsored by University of California, Irvine.

What drugs are being tested in NCT06682728?

Interventions in NCT06682728: Sacituzumab Govitecan (SG), Nivolumab.

What condition does NCT06682728 study?

NCT06682728 studies Urothelial Carcinoma, Muscle-invasive Bladder Cancer.

Is NCT06682728 still recruiting?

NCT06682728 is currently recruiting now. Last updated 26 March 2025.

Last reviewed 2025-03-26 · How we verify

NCT06682728

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Recruiting now Phase 2 Last updated 26 March 2025

What this trial tests

Phase 2 trial testing Sacituzumab Govitecan (SG) in Urothelial Carcinoma in 23 participants. Currently enrolling.

Timeline

15 November 2024

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	University of California, Irvine
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	15 November 2024
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Sacituzumab Govitecan (SG) — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
Muscle-invasive Bladder Cancer — all drugs for Muscle-invasive Bladder Cancer →

Sponsor

University of California, Irvine

Who can join

18 and older, any sex, with Urothelial Carcinoma or Muscle-invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications.
Shi R, Jia L, Lv Z, Cui J. · · 2025 · cited 2× · PMID 40909270 · DOI 10.3389/fimmu.2025.1632705
Strategic Combinations of Antibody-Drug Conjugates from 2023 to 2025: From Dual Therapies to Innovative ADC-Based Regimens.
Jang H, Chang JE. · · 2025 · PMID 41471096 · DOI 10.3390/pharmaceutics17121581
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
Cigliola A, Maiorano BA, Dengur D, Tateo V, et al · · 2025 · PMID 41463264 · DOI 10.3390/cancers17244017

Verify or expand the search:

Other trials of Sacituzumab Govitecan (SG)

Trials testing the same drug.

NCT07046455 — Trop-2 Targeted PET Probes in Advanced TNBC · NA · recruiting
NCT07251868 — Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study · recruiting
NCT06243393 — Sacituzumab Govitecan in Metastatic Colorectal Cancer · Phase 2, PHASE3 · recruiting
NCT07359404 — Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC · Phase 2 · enrolling by invitation
NCT04724018 — Sacituzumab Govitecan Plus EV in Metastatic UC · Phase 1, PHASE2 · recruiting

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other University of California, Irvine trials

Trials by the same sponsor.

NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06682728 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 26 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06682728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing